322 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Rank Status Study
21 Available Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Condition: Adenovirus
Intervention: Drug: Brincidofovir
22 No longer available A Prospective, Multiparametric Biomarker Study to Identify Predictors of Treatment Response and Resistance in Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib or Pemetrexed With the AIO-TRK-0114 Study (MARBLE)
Condition: Non-small-cell Lung Cancer With Somatic EGFR Mutations
Intervention: Other: Collection of tumor and blood specimen
23 Available Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Deflazacort
24 Available Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Conditions: Neurofibromatosis Type 2;   Severe Profound Sensorineural Hearing Loss
Intervention: Device: Nucleus Profile ABI541 Auditory Brainstem Implant
25 Available An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Condition: Urothelial Carcinoma
Intervention: Drug: Atezolizumab
26 Temporarily not available Autologous Platelet-rich Plasma (aPRP) for Complex Aortic Arch Surgerymacrovascular Operation
Condition: Autologous Blood Transfusion
Intervention: Procedure: Sorin XTRA/Sorin Group,
27 No longer available Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
Condition: Sarcoma
Intervention: Drug: aldoxorubicin
28 Available An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
29 Available Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders
Condition: Refractory Gastroesophageal Reflux Disease With Upper Gastrointestinal (GI) Symptoms, Gastroparesis, and Chronic Constipation
Intervention: Drug: Domperidone
30 Available Cannabidiol for Pediatric Epilepsy (Compassionate Use)
Condition: Refractory Childhood Epilepsy
Intervention: Drug: cannabidiol (CBD)
31 No longer available Rociletinib (CO-1686) USA Expanded Access Program
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Rociletinib
32 No longer available Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Elotuzumab
33 Available Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia
Conditions: Hyperinsulinemic Hypoglycemia, Persistent;   Congenital Hyperinsulinism;   Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Intervention: Drug: 18 F-DOPA
34 Available EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
Condition: Secondary AML
Intervention: Drug: CPX-351
35 Available Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography
Conditions: Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: 11C-choline;   Device: PET/CT Scan
36 Temporarily not available Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.
Condition: Sciatic Nerve Injury
Intervention: Biological: Autologous human Schwann cells
37 No longer available Triheptanoin (UX007) to Treat Citrate Transporter Deficiency
Conditions: Citrate Transporter Deficiency;   SLC13A5 Gene Mutation
Intervention: Drug: triheptanoin
38 Approved for marketing Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
Condition: Hypophosphatasia
Intervention: Biological: asfotase alfa
39 Available Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy
Condition: Oncology Patients With Gastroparesis
Intervention: Drug: Oral Domperidone
40 No longer available Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair
Condition: Sciatic Nerve Injury
Intervention: Biological: Autologous Human Schwann cells

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years